Please login to the form below

Not currently logged in
Email:
Password:

Hugh Cole leaves Shire for Ariad

Appointed chief business officer at company behind Iclusig

Ariad, Hugh ColeHugh Cole has left his role at Shire to join Ariad Pharmaceuticals as chief business officer.

In this role Cole will report to CEO Dr Harvey Berger and will be responsible for the company's global business and corporate development, licensing and strategic planning.

Cole spent seven years at Shire, most recently as senior VP, strategic planning and programme management. Prior to this he was a global franchise lead and VP, business development.

At Shire he gained experience in the orphan drugs market, which will benefit Ariad as it prepares to grow its portfolio of drugs targeted to treat rare, difficult-to-treat forms of cancer.

This includes its only current marketed product Iclusig, which is recommended to treat chronic myeloid leukaemia and T315I-positive Philadelphia chromosome positive acute lymphoblastic leukaemia.

The appointment of a chief business officer is a sign of confidence from Ariad, which last year faced safety concerns about Iclusig, but has since seen the drug backed by both the EMA and the FDA, although with new safety recommendations.

CEO Berger said: “[Cole] will be integral in seeking business and corporate development opportunities for Ariad, including a commercial partnership for Iclusig in Japan, as well as helping to further maximise our oncology pipeline.”

8th April 2014

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

Enabling market access through outcomes-based pricing
Outcomes-based pricing is a potential solution to create a link between product price and real-world outcomes, while at the same time facilitating patient access to new and innovative medicines....
Five companies 20 for 2020
20 for 2020 – Five pharma companies to watch
As a new decade gets into gear, we take a look at five pharma companies that have a lot riding on 2020...
The growing clinical importance of patient-reported outcomes (PROs)
Traditionally, the success or otherwise of medical treatments has been assessed by mortality or clinical assessments of health. However, patient self-reports of health are increasingly seen as central to the...

Infographics